Renaissance Technologies’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-722,390
| Closed | -$59K | – | 4580 |
|
|
2022
Q4 | $59K | Sell |
722,390
-634,556
| -47% | -$80.5K | ﹤0.01% | 3768 |
|
|
2022
Q3 | $176K | Sell |
1,356,946
-279,289
| -17% | -$58.8K | ﹤0.01% | 3424 |
|
|
2022
Q2 | $466K | Buy |
1,636,235
+1,464,317
| +852% | +$379K | ﹤0.01% | 3202 |
|
|
2022
Q1 | $54K | Sell |
171,918
-34,117
| -17% | -$36.5K | ﹤0.01% | 3900 |
|
|
2021
Q4 | $474K | Buy |
206,035
+91,837
| +80% | +$271K | ﹤0.01% | 3105 |
|
|
2021
Q3 | $264K | Buy |
114,198
+16,147
| +16% | +$61.2K | ﹤0.01% | 3121 |
|
|
2021
Q2 | $536K | Sell |
98,051
-32,500
| -25% | -$175K | ﹤0.01% | 2939 |
|
|
2021
Q1 | $685K | Sell |
130,551
-35,100
| -21% | -$192K | ﹤0.01% | 2786 |
|
|
2020
Q4 | $571K | Sell |
165,651
-41,100
| -20% | -$117K | ﹤0.01% | 2762 |
|
|
2020
Q3 | $407K | Sell |
206,751
-66,500
| -24% | -$153K | ﹤0.01% | 2895 |
|
|
2020
Q2 | $702K | Sell |
273,251
-16,100
| -6% | -$29.1K | ﹤0.01% | 2724 |
|
|
2020
Q1 | $480K | Sell |
289,351
-21,165
| -7% | -$43.2K | ﹤0.01% | 2777 |
|
|
2019
Q4 | $187K | Buy |
310,516
+3,500
| +1% | +$2.59K | ﹤0.01% | 3214 |
|
|
2019
Q3 | $310K | Buy |
307,016
+3,700
| +1% | +$4.99K | ﹤0.01% | 3026 |
|
|
2019
Q2 | $440K | Buy |
303,316
+9,900
| +3% | +$15.3K | ﹤0.01% | 3044 |
|
|
2019
Q1 | $493K | Buy |
293,416
+6,100
| +2% | +$8.99K | ﹤0.01% | 2923 |
|
|
2018
Q4 | $290K | Buy |
287,316
+5,400
| +2% | +$9.32K | ﹤0.01% | 3033 |
|
|
2018
Q3 | $567K | Buy |
281,916
+12,800
| +5% | +$27.5K | ﹤0.01% | 2814 |
|
|
2018
Q2 | $662K | Buy |
269,116
+9,500
| +4% | +$26.4K | ﹤0.01% | 2749 |
|
|
2018
Q1 | $797K | Buy |
259,616
+18,600
| +8% | +$65.6K | ﹤0.01% | 2743 |
|
|
2017
Q4 | $966K | Buy |
241,016
+24,000
| +11% | +$73K | ﹤0.01% | 2670 |
|
|
2017
Q3 | $747K | Buy |
217,016
+24,300
| +13% | +$68.8K | ﹤0.01% | 2677 |
|
|
2017
Q2 | $569K | Buy |
192,716
+157,700
| +450% | +$515K | ﹤0.01% | 2727 |
|
|
2017
Q1 | $56K | Buy |
35,016
+23,100
| +194% | +$38.3K | ﹤0.01% | 3132 |
|
|
2016
Q4 | $17K | Buy |
+11,916
| New | +$18.8K | ﹤0.01% | 3207 |
|
|
2015
Q3 | – | Sell |
-16,266
| Closed | -$71K | – | 3427 |
|
|
2015
Q2 | $71K | Sell |
16,266
-31,987
| -66% | -$96.3K | ﹤0.01% | 3127 |
|
|
2015
Q1 | $172K | Buy |
+48,253
| New | +$198K | ﹤0.01% | 2919 |
|
|
2014
Q3 | – | Sell |
-1,910
| Closed | -$18K | – | 3003 |
|
|
2014
Q2 | $18K | Sell |
1,910
-524
| -22% | -$6.12K | ﹤0.01% | 2744 |
|
|
2014
Q1 | $33K | Sell |
2,434
-1,981
| -45% | -$32.3K | ﹤0.01% | 2773 |
|
|
2013
Q4 | $103K | Buy |
+4,415
| New | +$120K | ﹤0.01% | 2720 |
|
Other funds holding STAB
Renaissance Technologies's STAB Position: Q1 2023 in Review
Renaissance Technologies sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 722,390 shares — an estimated $59K sold.
Renaissance Technologies first reported a position in STAB in Q4 2013 and held it in 30 quarters. The position peaked at $966K in Q4 2017. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.
- Renaissance Technologies reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Renaissance Technologies sold 722,390 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $59K.
- Renaissance Technologies first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2013 and held it in 30 quarters.
- Renaissance Technologies's Statera Biopharma, Inc. Common Stock position peaked at $966K in Q4 2017.
- 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.